CN107164314A - 一种屏障加强的体外重组表皮模型的构建方法 - Google Patents
一种屏障加强的体外重组表皮模型的构建方法 Download PDFInfo
- Publication number
- CN107164314A CN107164314A CN201710460506.4A CN201710460506A CN107164314A CN 107164314 A CN107164314 A CN 107164314A CN 201710460506 A CN201710460506 A CN 201710460506A CN 107164314 A CN107164314 A CN 107164314A
- Authority
- CN
- China
- Prior art keywords
- cell
- epidermis
- epidermal
- culture
- strengthened
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002615 epidermis Anatomy 0.000 title claims abstract description 66
- 230000004888 barrier function Effects 0.000 title claims abstract description 33
- 238000005215 recombination Methods 0.000 title claims abstract description 19
- 230000006798 recombination Effects 0.000 title claims abstract description 19
- 238000010276 construction Methods 0.000 title claims abstract description 15
- 210000003491 skin Anatomy 0.000 claims abstract description 34
- 210000001519 tissue Anatomy 0.000 claims abstract description 21
- 210000002514 epidermal stem cell Anatomy 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000000926 separation method Methods 0.000 claims abstract description 10
- 230000004069 differentiation Effects 0.000 claims abstract description 6
- 230000000877 morphologic effect Effects 0.000 claims abstract description 5
- 210000000498 stratum granulosum Anatomy 0.000 claims abstract description 4
- 210000001339 epidermal cell Anatomy 0.000 claims description 37
- 239000007788 liquid Substances 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 33
- 235000015097 nutrients Nutrition 0.000 claims description 25
- 238000004113 cell culture Methods 0.000 claims description 12
- 230000001079 digestive effect Effects 0.000 claims description 12
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 12
- 239000010410 layer Substances 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 108010019160 Pancreatin Proteins 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 229940055695 pancreatin Drugs 0.000 claims description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 101800001401 Activation peptide Proteins 0.000 claims description 6
- 102400000069 Activation peptide Human genes 0.000 claims description 6
- 229960000890 hydrocortisone Drugs 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 229920000515 polycarbonate Polymers 0.000 claims description 6
- 239000004417 polycarbonate Substances 0.000 claims description 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 4
- 229930024421 Adenine Natural products 0.000 claims description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 102000002734 Collagen Type VI Human genes 0.000 claims description 4
- 108010043741 Collagen Type VI Proteins 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 102000002070 Transferrins Human genes 0.000 claims description 4
- 108010015865 Transferrins Proteins 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 230000009514 concussion Effects 0.000 claims description 4
- 210000002808 connective tissue Anatomy 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 108010007093 dispase Proteins 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- 230000001817 pituitary effect Effects 0.000 claims description 4
- 239000002356 single layer Substances 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 230000035699 permeability Effects 0.000 abstract description 15
- 238000012360 testing method Methods 0.000 abstract description 13
- 239000000243 solution Substances 0.000 description 26
- 238000007792 addition Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108010051618 macrophage stimulatory lipopeptide 2 Proteins 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 Caffeine Acetonitrile Chemical compound 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007682 dermal toxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
Description
样品 | 流动相 | 流速(ml/min) | 检测波长(nm) | 温度 |
咖啡因 | 乙腈:水:甲醇(10:70:20 v/v/v) | 1 | 270 | 25℃ |
氢化可的松 | 乙腈:水:(40:60 v/v) | 1 | 242 | 25℃ |
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010689504.4A CN111909888A (zh) | 2017-06-18 | 2017-06-18 | 用于构建屏障加强体外重组表皮模型的ta培养液 |
CN201710460506.4A CN107164314B (zh) | 2017-06-18 | 2017-06-18 | 一种屏障加强的体外重组表皮模型的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710460506.4A CN107164314B (zh) | 2017-06-18 | 2017-06-18 | 一种屏障加强的体外重组表皮模型的构建方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010689504.4A Division CN111909888A (zh) | 2017-06-18 | 2017-06-18 | 用于构建屏障加强体外重组表皮模型的ta培养液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107164314A true CN107164314A (zh) | 2017-09-15 |
CN107164314B CN107164314B (zh) | 2020-11-20 |
Family
ID=59818773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710460506.4A Active CN107164314B (zh) | 2017-06-18 | 2017-06-18 | 一种屏障加强的体外重组表皮模型的构建方法 |
CN202010689504.4A Pending CN111909888A (zh) | 2017-06-18 | 2017-06-18 | 用于构建屏障加强体外重组表皮模型的ta培养液 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010689504.4A Pending CN111909888A (zh) | 2017-06-18 | 2017-06-18 | 用于构建屏障加强体外重组表皮模型的ta培养液 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN107164314B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108048393A (zh) * | 2017-12-12 | 2018-05-18 | 谢举临 | 一种新型的快速扩增皮肤表皮基底干细胞的方法 |
CN111117945A (zh) * | 2019-12-31 | 2020-05-08 | 广东博溪生物科技有限公司 | 含黑色素的表皮皮肤模型及其构建方法和应用 |
CN112391334A (zh) * | 2020-11-17 | 2021-02-23 | 深圳清华大学研究院 | 表皮细胞悬液的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103884835A (zh) * | 2014-03-12 | 2014-06-25 | 珀莱雅化妆品股份有限公司 | 一种在聚碳酸酯膜上构建用于检测化妆品刺激性的组织工程表皮的方法 |
CN104459145A (zh) * | 2013-09-13 | 2015-03-25 | 王阿慧 | 一种化妆品检测 |
CN105734009A (zh) * | 2016-04-01 | 2016-07-06 | 陕西博溪生物科技有限公司 | 体外重组人体皮肤表皮模型及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9175260B2 (en) * | 2007-01-30 | 2015-11-03 | TheUniversity of Georgia Research Foundation, Inc. | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC) |
US20130045267A1 (en) * | 2010-02-05 | 2013-02-21 | University Of Rochester | Methods of using agents that modulate claudin expression |
WO2014066649A1 (en) * | 2012-10-26 | 2014-05-01 | The Regents Of The University Of California | A strategy for engineering various 3d tissues, organoids and vasculature |
CN104830772A (zh) * | 2015-05-28 | 2015-08-12 | 深圳富利鑫健康产业发展有限公司 | 一种造血干细胞培养基及其应用和干细胞培养方法 |
-
2017
- 2017-06-18 CN CN201710460506.4A patent/CN107164314B/zh active Active
- 2017-06-18 CN CN202010689504.4A patent/CN111909888A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104459145A (zh) * | 2013-09-13 | 2015-03-25 | 王阿慧 | 一种化妆品检测 |
CN103884835A (zh) * | 2014-03-12 | 2014-06-25 | 珀莱雅化妆品股份有限公司 | 一种在聚碳酸酯膜上构建用于检测化妆品刺激性的组织工程表皮的方法 |
CN105734009A (zh) * | 2016-04-01 | 2016-07-06 | 陕西博溪生物科技有限公司 | 体外重组人体皮肤表皮模型及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
DAVID T. WOODLEY等: "Type IV Collagen and Fibronectin Enhance Human Keratinocyte Thymidine Incorporation and Spreading in the Absence of Soluble Growth Factors", 《THE JOURNAL OF INVESTIGATIVE DERMATOLOGY》 * |
李中良 等: "用于替代皮肤刺激试验的组织工程表皮模型的构建研究", 《中国修复重建外科杂志》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108048393A (zh) * | 2017-12-12 | 2018-05-18 | 谢举临 | 一种新型的快速扩增皮肤表皮基底干细胞的方法 |
CN111117945A (zh) * | 2019-12-31 | 2020-05-08 | 广东博溪生物科技有限公司 | 含黑色素的表皮皮肤模型及其构建方法和应用 |
CN111117945B (zh) * | 2019-12-31 | 2023-11-07 | 广东博溪生物科技有限公司 | 含黑色素的表皮皮肤模型及其构建方法和应用 |
CN112391334A (zh) * | 2020-11-17 | 2021-02-23 | 深圳清华大学研究院 | 表皮细胞悬液的制备方法 |
CN112391334B (zh) * | 2020-11-17 | 2023-03-21 | 深圳清华大学研究院 | 表皮细胞悬液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111909888A (zh) | 2020-11-10 |
CN107164314B (zh) | 2020-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0866849B1 (en) | Solid support for use in cell cultivation, especially for the cultivation of liver cells, biological reactor containing said solid support and the use thereof in a bio-artificial liver system | |
CN104726396A (zh) | 一种全层皮肤模型的构建方法 | |
CN107164314A (zh) | 一种屏障加强的体外重组表皮模型的构建方法 | |
WO2012063925A1 (ja) | 細胞培養チャンバーとその製造方法、および、この細胞培養チャンバーを利用した組織モデルとその作製方法 | |
CN107496348A (zh) | 一种用于组织损伤修复的水凝胶及制备方法 | |
CN107308494A (zh) | 一种注射用胶原蛋白、制备方法及填充剂 | |
CN104399125B (zh) | 表皮干细胞向汗腺样上皮细胞分化的方法 | |
CN109010247A (zh) | 一种自体成纤维细胞来源的外泌体冻干粉的应用及制备方法 | |
CN107523533A (zh) | 自体皮肤成纤维细胞、prp及胶原蛋白液的获取方法 | |
CN101549171A (zh) | 一种ⅱ型胶原海绵支架及其用途 | |
CN107287152A (zh) | 用于化妆品抗衰检测的双层皮肤模型的构建方法及培养液 | |
CN108085303A (zh) | 一种活性虫草酵素制备的优化方法及其在化妆品中的应用 | |
CN107164315A (zh) | 一种用于体外皮肤刺激性检测的重组表皮模型的构建方法 | |
CN107083365A (zh) | 一种中国人肺腺癌细胞系及其应用 | |
CN107164308A (zh) | 一种黑素细胞均匀生长的培养方法 | |
Cheng et al. | In vitro culture of tumour-derived hepatocytes in decellularised whole-liver biological scaffolds | |
CN106568911A (zh) | 一种离体状态的模拟皮肤模型 | |
CN107287151A (zh) | 一种含黑色素细胞的体外皮肤测试模型的构建方法 | |
CN105085938B (zh) | 白芨多糖水凝胶、培养基质及其应用与诱导脐带间充质干细胞向角膜上皮细胞分化的方法 | |
CN1560225A (zh) | 双层活性皮肤体外构建的灌注式生物反应器系统 | |
CN104459145A (zh) | 一种化妆品检测 | |
CN104087554B (zh) | 一种人胸腺瘤细胞系及其用途 | |
CN102091352A (zh) | 一种含有汗腺的组织工程皮肤模型的构建方法 | |
CN102344904B (zh) | 一种猪细胞培养基 | |
CN105396136A (zh) | CCN1(Cyr61)在治疗皮肤损伤及皮肤萎缩相关疾病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240129 Address after: Room 305, 3rd Floor, Building B5, Standard Factory Building, Modern Textile Industry Park, Baqiao District, Xi'an City, Shaanxi Province, 710038 Patentee after: Shaanxi Boxi General Testing Technology Co.,Ltd. Country or region after: China Address before: 523808 room 08, 1 / F, cooperation center, Dongguan Taiwan Biotechnology Center, No.1 Taoyuan Road, Taiwan hi tech park, Songshanhu hi tech Industrial Development Zone, Dongguan City, Guangdong Province Patentee before: GUANGDONG BIOCELL BIOTECHNOLOGY Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |